Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | P2RX3 | P56373 | 1/20 | 1.00 |
| ▸ | ATP6AP1 | Q15904 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bafilomycin A1 SCHEMBL20768056 | 1.00 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL27111880 | 1.00 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL13990314 | 1.00 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL13778448 | 1.00 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL29355819 | 1.00 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL29396438 | 1.00 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL13775181 | 1.00 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL20768057 | 1.00 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| SCHEMBL23550703 | 0.94 | ADORA3 (0.88) | ADORA3P2RX3ATP6AP1GLATHRB | |
| SCHEMBL22590602 | 0.94 | ADORA3 (0.88) | ADORA3P2RX3ATP6AP1GLATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4742891-A2 | METHOD OF GENOME-EDITING | Universiteit Gent (BE) | 2026-05-20 | — | — | EP | claimed |
| US-20250295668-A1 | METHODS FOR INDUCING COLANIC ACID BIOSYNTHESIS | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2025-09-25 | — | — | US | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| CN-119574409-A | Kit for integrally detecting aging cells and apoptotic cells, detection method and application thereof | 天津医科大学 | 2025-03-07 | — | — | CN | claimed |
| WO-2025012316-A2 | METHOD OF GENOME-EDITING | UNIVERSITEIT GENT (BE) | 2025-01-16 | — | — | WO | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | claimed |
| CN-118121602-A | Application of chloroquinaldol in preparation of GPX4 protein degradation products | 广西大学 | 2024-06-04 | — | — | CN | claimed |
| WO-2023172669-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-14 | — | — | WO | claimed |
| US-20230236169-A1 | NANOPLASMONIC BIOSENSOR FOR DETECTING AUTOPHAGY MARKER WITH HIGH SENSITIVITY, AND METHOD OF DETECTING AUTOPHAGY MARKER AND METHOD OF SCREENING DRUG CANDIDATE USING SAME | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2023-07-27 | — | — | US | claimed |
| CN-114364804-A | Methods and compositions for improving adeno-associated virus (AAV) assembly | 马萨诸塞眼科耳科诊所 | 2022-04-15 | — | — | CN | claimed |
| EP-4742891-A2 | METHOD OF GENOME-EDITING | Universiteit Gent (BE) | 2026-05-20 | — | — | EP | disclosed |
| CN-122070367-A | Method for determining lysosomal activity | 东方酵母工业株式会社 | 2026-05-19 | — | — | CN | disclosed |
| US-20260103727-A1 | THERAPEUTIC RECOMBINANT VIRUSES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-16 | — | — | US | disclosed |
| US-12594258-B2 | Inhibitors of MHC-I Nef downmodulation for treating HIV | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-04-07 | — | — | US | disclosed |
| US-20220054433-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220054445-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID AND AN AUTOPHAGY INHIBITOR | RAFAEL PHARMACEUTICALS INC (US) | 2022-02-24 | — | — | US | disclosed |
| WO-2022035244-A1 | COLON CANCER DIAGNOSIS OR DETECTION COMPOSITION FOR PREDICTING RESPONSE TO DRUG, AND COMPOSITION FOR PREVENTING OR TREATING COLON CANCER | 한국과학기술연구원 | 2022-02-17 | — | — | WO | disclosed |
| US-20220031849-A1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-03 | — | — | US | disclosed |
| US-20220023233-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031849-A1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | GPR88, GPR65, ARRB1 | ADORA3 1468/4885P2RX3 503/4885ATP6AP1 1340/4885 |
| US-12594258-B2 | Inhibitors of MHC-I Nef downmodulation for treating HIV | HLA-DRB1, CD74, HLA-C | ADORA3 1260/4885P2RX3 3595/4885ATP6AP1 458/4885 |
| US-20220054445-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID AND AN AUTOPHAGY INHIBITOR | BECN1, ATG7, SQSTM1 | ADORA3 1936/4885P2RX3 2806/4885ATP6AP1 3099/4885 |
| US-20220054433-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | MUC1, TMIGD3, TMED9 | ADORA3 4451/4885P2RX3 3797/4885ATP6AP1 3359/4885 |
| US-20260103727-A1 | THERAPEUTIC RECOMBINANT VIRUSES | RBM26, EGFR, ERBB2 | ADORA3 1809/4885P2RX3 1616/4885ATP6AP1 1385/4885 |
| US-20220023233-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | MUC1, TMIGD3, TMED9 | ADORA3 4451/4885P2RX3 3797/4885ATP6AP1 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.